A substantial takeover premium highlights the value of differentiated medicines, while Serina Therapeutics and Eupraxia Pharmaceuticals approach clinical milestones of their own.
October 19, 2026
Biotechnology investors received a rather emphatic reminder Monday that pharmaceutical innovation can still command a premium, even…